缬沙坦与苯磺酸左旋氨氯地平治疗原发性高血压的疗效及对血尿酸影响的比较研究

目的：比较缬沙坦与苯磺酸左旋氨氯地平治疗原发性高血压的疗效及对血尿酸的影响。方法将84例原发性高血压患者随机分为治疗组和对照组各42例。对照组予以缬沙坦片80mg，每日1次。治疗组予以苯磺酸左旋氨氯地平片5mg，每日1次。两组疗程均为8周。结果两组患者治疗后收缩压、舒张压与同组治疗前比较，差异均有统计学意义（P＜0.01）。治疗组治疗后收缩压、舒张压与对照组比较，差异均无统计学意义（P＞0.05）。治疗组治疗后血压达标有26例，达标率为61.90%，对照组治疗后血压达标有17例，达标率为54.76%。两组血压达标率比较，差异无统计学意义（P＞0.05）。治疗后，治疗组血尿酸与对照组比较，差异具有统计学意义（P＜0.01）。结论缬沙坦与苯磺酸左旋氨氯地平均能改善原发性高血压患者的血压水平，且缬沙坦能显著降低原发性高血压患者血尿酸水平。

A comparative study of the efficacy of valsartan and levamlodipine besylate in the treatment of essential hypertension and its effect on blood uric acid

Objective To compare the efficacy of valsartan and Levamlodipine besylate in the treatment of essential hypertension and its effect on blood uric acid. Methods 84 patients with essential hypertension were randomly divided into treatment group and control group equally. Patients in control group were given valsartan tablets 80mg, once a day while patients in treatment group were given levamlodipine besylate tablets 5 mg, once a day for a course of eight weeks for each group. Results A significant difference was observed in systolic blood pressure （SBP） and diastolic blood pressure （DBP） before and after-treatment in the same group（P〈0.01） while SBP and DBP between treatment group and control after treatment showed no significant difference（P 〉 0.05）. Blood pressure in 26 cases （61.90%） reached acceptable level in treatment group after treatment while there were 17 （54.76%） cases in control group which showed no significant difference in the two groups（P〉0.05）. Blood uric acid in the two groups showed significant difference after treatment （P 〈 0.01）. Conclusion Both valsartan and Levamlodipine besylate can improve the BP level in patients with essential hypertension and valsartan can significantly reduce the level of blood uric acid in patients with essential hypertension.